Acadia Pharma (ACAD) Misses Q4 EPS by 2c

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26).

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• The LGL Group (LGL) Misses Q2 EPS by 8c
• L3Harris names Sam Mehta CEO after Kubasik exits over conduct issues